Download Files:
Firmonertinib (mesylate)
$220 – $1,375
Products Details
Product Description
– Firmonertinib (Alflutinib) mesylate is is a potent inhibitor of EGFR. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC)[1].
Web ID
– HY-112870A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C29H35F3N8O5S
Citations
– Patent. US20220177473A1.|JTO Clin Res Rep. 2023 Nov 27, 100614.
References
– [1]Y. Shi, et al. P2.03-028 Third Generation EGFR Inhibitor AST2818 (Alflutinib) in NSCLC Patients with EGFR T790M Mutation: A phase1/2 Multi-Center Clinical Trial.
CAS Number
– 2130958-55-1
Molecular Weight
– 664.70
Compound Purity
– 99.96
SMILES
– C=CC(NC1=CC(NC2=NC=CC(C3=CN(C)C4=C3C=CC=C4)=N2)=C(OCC(F)(F)F)N=C1N(CCN(C)C)C)=O.CS(=O)(O)=O
Clinical Information
– Launched
Research Area
– Cancer
Solubility
– DMSO : 5 mg/mL (ultrasonic)
Target
– EGFR
Isoform
– EGFR/ErbB1/HER1
Pathway
– JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
